320 related articles for article (PubMed ID: 10814748)
1. Neoral use in the cardiac transplant recipient.
Valantine H
Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
[TBL] [Abstract][Full Text] [Related]
2. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
Hoyer PF
Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
6. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation.
Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA
Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplantation; 1999 Jun; 67(11):1411-7. PubMed ID: 10385078
[TBL] [Abstract][Full Text] [Related]
8. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
[TBL] [Abstract][Full Text] [Related]
9. Neoral use in the renal transplant recipient.
Belitsky P
Transplant Proc; 2000 May; 32(3A Suppl):10S-19S. PubMed ID: 10814746
[TBL] [Abstract][Full Text] [Related]
10. Experience with neoral versus sandimmune in primary liver transplant recipients.
Pinson CW; Chapman WC; Wright JK; Hunter EB; Awad JA; Raiford DS; Payne JL; Geevarghese S; Blair TK; Van Buren DH
Transpl Int; 1998; 11 Suppl 1():S278-83. PubMed ID: 9664997
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
[TBL] [Abstract][Full Text] [Related]
12. Conversion from Sandimmune to Neoral in organ transplant recipients.
Bartucci MR; Bayer L; Brooks BK; Chandler L; Himes V; Meiergerd D; Newby B; Satmary NT; Shieck V
J Transpl Coord; 1998 Dec; 8(4):227-33; quiz 234-5. PubMed ID: 10205463
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
14. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group.
Brennan DC; Barbeito R; Burke J; Brayman K; Greenstein S; Chang T
Kidney Int; 1999 Aug; 56(2):685-91. PubMed ID: 10432409
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
16. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.
Hausen B; Ikonen T; Briffa N; Berry GJ; Christians U; Robbins RC; Hook L; Serkova N; Benet LZ; Schuler W; Morris RE
Transplantation; 2000 Jan; 69(1):76-86. PubMed ID: 10653384
[TBL] [Abstract][Full Text] [Related]
17. Neoral in de novo liver transplantation: adequate immunosuppression without intravenous cyclosporine.
Levy GA; Rasmussen A; Mayer AD; Jamieson NV; Neuhaus P
Liver Transpl Surg; 1997 Nov; 3(6):571-7. PubMed ID: 9404955
[TBL] [Abstract][Full Text] [Related]
18. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
[TBL] [Abstract][Full Text] [Related]
19. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
20. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
